Icra sees pharma industry growth tapering to 7-10% over FY18-FY20Post published:July 4, 2017Post category:Industry NewsThe Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report Source: Livemint.com (http://www.livemint.com/rss/industry)Read more articles Previous PostIndoStar Capital close to acquiring ICICI Home Finance Next PostGST rates: Footwear to cost more as firms look to increase prices by 5-7% You Might Also Like Standard Chartered, IDBI Bank, Yes Bank top compliance rankings in survey June 14, 2017 Flipkart, Rivigo termed as breakthrough brands that define progress. Here are the details May 24, 2017 Leviton announces INFORM intelligent platform November 16, 2018
Flipkart, Rivigo termed as breakthrough brands that define progress. Here are the details May 24, 2017